Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation

Background. The implementation of tyrosine kinase inhibitors into clinical practice improved treatment outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for these patients. The study objective is to analyze clinica...

Full description

Bibliographic Details
Main Authors: E. V. Borodavina, P. A. Isaev, A. Yu. Shurinov, P. O. Rumyantsev, V. V. Krylov, K. M. Petrosyan, A. D. Kaprin, S. A. Ivanov, S. O. Podvyaznikov, I. S. Romanov, A. M. Mudunov, K. Yu. Slashchuk, R. S. Zhikhorev, M. V. Volkonsky, R. M. Chagova, I. R. Suslova, A. I. Khryapa, A. Kh. Lepshokova, N. L. Fadeeva, A. R. Safarova, L. P. Kaleykina, E. V. Lymar, E. M. Chernyakova, O. A. Snezhko, A. E. Zinkovskaya, F. F. Mufazalov, E. S. Kuzmina, Yu. V. Druzhinina, Sh. I. Musin, M. R. Mukhitova, A. I. Khasanova, S. Z. Safina, S. L. Kirienko
Format: Article
Language:Russian
Published: ABV-press 2020-04-01
Series:Опухоли головы и шеи
Subjects:
ленватиниб, радиойодрезистентный рак щитовидной железы, клиническая практика, выживаемость без прогрессирования
Online Access:https://ogsh.abvpress.ru/jour/article/view/478

Similar Items

Similar Items